Latest news with #Novo
Scottish Sun
a day ago
- Sport
- Scottish Sun
‘I don't know why I can't get a job' – Rangers cult hero quizzed on whether Old Firm past is denying him opportunities
He reckons people still think he acts like he did on the pitch - and called one of his old Celtic enemies "one of the nicest people you can meet" OUT OF THE GAME OUT OF THE GAME 'I don't know why I can't get a job' – Rangers cult hero quizzed on whether Old Firm past is denying him opportunities Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) FORMER Rangers star Nacho Novo is desperate for a job in football management. But he has been left scratching his head as to why he hasn't had more opportunities. Sign up for the Rangers newsletter Sign up 3 Nacho Novo was a cult hero during his time at Rangers Credit: Alamy 3 Novo during his time with Lexington SC in the USA 3 He's been talking about his hunt for a full-time managerial job Credit: LET ME BE FRANK The ex-Gers striker returned to Scottish football with Drumchapel United as part of the coaching staff last year. Drumchapel currently ply their trade in the West of Scotland Football League Premier Division - the sixth tier of the SPFL pyramid. While Novo admits he loves working with the part-timers but has found himself questioning why, after such a glittering playing career, that he's been passed over for other coaching jobs. It was reported last year that Novo applied for the Raith Rovers job when Ian Murray was bizarrely sacked just one game into the season. But the Kirkcaldy club appointed Neil Collins as his successor. Novo, 46, retired in 2017 after having played in the top flights of Spain, Scotland and Poland and winning seven trophies (six with Gers and one with Legia Warsaw). He went through his coaching badges before landing his first job as a coach at Lexington SC in USL League One (the third tier of football in the United States). He initially served as assistant manager and as the head coach of the Under-23s before being promoted to the interim role in September 2023. But he left and within a year had returned to Scotland. After a full season with Drumchapel, Novo has admitted he is still chasing a dream of opening a football academy if he doesn't get a full-time job in management. Rangers fans react as 49ers takeover completed Speaking on the Let Me Be Frank podcast, Novo said: "I've been at Drumchapel for a whole season now and I love it. "Especially because it's proper football, that's how I'd say it! Proper tackles! "We had a good group of boys, some have been pros. They did well this season." Drumchapel finished sixth in the Premier Division this season. And despite his reputation as a former Rangers fan favourite, Novo insists he never had any added grief on the sidelines over the past year. But he does wonder if his association to the Light Blues has held him back when it comes to applying for other jobs higher up the food chain. He said: "I don't know why I can't get a job in football as a coach or anything like that. "Is it because of Rangers? I don't know. "It's probably because of how I was on the park but how I was on the park is not how I am as a person outside." Expanding on that point, Novo talked about how former Celtic foes like John Hartson remain good family friends to this day. And how one-time arch rival Neil Lennon is one of the nicest people he's met in football. Novo said: "People think about Neil Lennon for example, they think he's terrible, that he acts like he did on the pitch. He's one of the nicest guys you'll ever meet. "John Hartson, he's a good friend of my family. "We played on the same park and hated each other but we respected each other. "On the pitch we were enemies and that was my mentality but outside of that I'm very quiet and a family man." Novo has been approached for a scouting job that would see him scour Scotland and the north of England for talent. But his main ambition is to open a cross-border football academy that would link his homeland and his adopted home. He said: "I tried to open a football academy here and in Spain. "I wanted to bring clubs from Scotland over to Spain for a tournament and bring Spanish teams here for the same thing. "But that takes a lot of insurance to do it right, a lot of admin and red tape. "That's my idea at the moment." Keep up to date with ALL the latest news and transfers at the Scottish Sun football page
CNBC
3 days ago
- Business
- CNBC
Hims to cut 4% of workforce amid ban on weight-loss drug copies
NEW YORK, May 30 (Reuters) - Telehealth platform Hims & Hers (HIMS.N), opens new tab will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy. A U.S. Food and Drug Administration ban on compounded copies of Wegovy, made by Novo Nordisk ( opens new tab, took effect on May 22. Hims shares have since dropped 14%. The company confirmed the job cuts in a statement on Friday. On Saturday, it said that the reductions were not related to the compounding ban. Hims did not provide details about the roles that were cut, but said they were implemented across teams. "These changes are focused on sharpening how we execute, without affecting our priorities or the specialties we're committed to," a company spokesperson said regarding the layoffs. Hims still plans to hire for roles related to its long-term growth strategy. The company recently announced an agreement with Novo to help patients access brand-name Wegovy. It plans to enter the market for low testosterone and menopause treatments and is looking at offerings to improve longevity and sleep. Bloomberg News reported the job cuts earlier on Friday. In 2022, the FDA declared a shortage of Wegovy, which has been shown to help patients lose around 15% of their body weight. That declaration allowed compounding pharmacies to produce the drug to meet demand. Hims began offering copies of Wegovy in 2024, often at far lower prices than the brand-name version. That boosted subscriptions to the Hims telehealth platform, with revenue up 111% on a yearly basis during the first quarter of 2025. Wegovy copies and similar GLP-1 weight-loss drugs accounted for $200 million of the company's $1.5 billion revenue in 2024. The FDA in February said Wegovy was no longer in shortage and ended the exception that allowed sale of mass compounded copies of the patented medication. Hims and its rivals have pivoted to what they say are customized copies of Wegovy that should not be subject to the FDA decision, featuring smaller doses or allowing for a more individualized plan for increasing dosage than offered by Novo. But analysts said that personalization strategy may not be enough to stave off new legal challenges from Novo. "It remains to be seen whether HIMS method of personalization (titration and dosage) is enough to meet the compounding clinical exemption need," said Jailendra Singh, a healthcare analyst at Truist.
Scottish Sun
3 days ago
- Sport
- Scottish Sun
‘It was complicated' – Rangers cult hero who turned down Celtic opens up on why he chose Ibrox
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) HE famously turned down Celtic to join Rangers - then scored six goals against the Hoops while playing for the Light Blues. Rangers legend Nacho Novo had the choice of Glasgow's big two after a standout season in Scotland with Dundee. Sign up for Scottish Sun newsletter Sign up 2 Nacho Novo loved playing for Rangers Credit: Getty 2 But he could have opted to wear green and white instead Novo, now 46, moved to Scotland in 2001 when his agent recommended a shock switch to Raith Rovers - despite Valencia also being on his trail. After a season in Kirkcaldy he travelled up the A92 to Dens Park, before heading back down to Glasgow when Rangers came calling. But while the Light Blues had him on their radar for some time, it was actually Martin O'Neill who made the first official approach. Novo, however, only had Ibrox on his mind. Speaking to the Let Me Be Frank podcast, Novo revealed: "I knew Rangers were interested in me for a while. I spoke to my agent, I knew there were a big club. "It was complicated at the time because Dundee were entering administration so the chairman wanted to get as much money as possible, which is understandable. "Celtic wanted to speak to me and they made me to go Celtic Park. They said there wasn't going to be any cameras, and of course the first thing I saw were cameras. "I spoke with Martin O'Neill but Rangers were in for me for a long time, while Celtic hadn't been. "I knew Mikel Arteta, I knew Ronald (De Boer), Shota (Arveladze) and Claudio Caniggia. "I used to go to Glasgow for something to eat and things like that, so I had friends there (at Rangers) already. Rangers fans react as 49ers takeover completed "I knew I would feel more comfortable going there. "I remember before that I went to the Scottish Cup final - Celtic vs Rangers - and I sat in the Rangers end when Fergie scored that free-kick. "Being there and seeing the atmosphere, you can't beat that. I think it's the best derby in the entire world. "I just got that feeling." Novo spent six years in Glasgow and lifted the same number of trophies during that time. He clinched the league and League Cup double in his first season under Alex McLeish. Novo was Rangers' top goal scorer that campaign and he went on to score 70 goals for the club in total, leaving Ibrox in 2010 to head back to Spain. Keep up to date with ALL the latest news and transfers at the Scottish Sun football page
Yahoo
4 days ago
- Business
- Yahoo
Hims to cut 4% of workforce amid ban on weight-loss drug copies
By Amina Niasse NEW YORK (Reuters) -Telehealth platform Hims & Hers said on Friday it will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy. A U.S. Food and Drug Administration ban on compounded copies of Wegovy, made by Novo Nordisk, took effect on May 22. Hims shares have since dropped 14%. The company said it is seeking new opportunities for growth, including an agreement with Novo to help patients access Wegovy. Hims plans to enter the market for low testosterone and menopause treatments and is looking at offerings to improve longevity and sleep. "These changes are focused on sharpening how we execute, without affecting our priorities or the specialties we're committed to," a company spokesperson said regarding the layoffs. Hims still plans to hire for roles related to its long-term growth plans. Bloomberg News reported the job cuts earlier on Friday. In 2022, the FDA declared a shortage of Wegovy, which has been shown to help patients lose around 15% of their body weight. That declaration allowed compounding pharmacies to produce the drug to meet demand. The FDA in February said Wegovy was no longer in shortage and ended the exception that allowed sale of mass compounded copies of the patented medication. Hims began offering copies of Wegovy in 2024, often at far lower prices than the brand-name version. That boosted subscriptions to the Hims telehealth platform, with revenue up 111% on a yearly basis during the first quarter of 2025. Wegovy copies and similar GLP-1 weight-loss drugs accounted for $200 million of the company's $1.5 billion revenue in 2024. Hims and its rivals have pivoted to what they say are customized copies of Wegovy that should not be subject to the FDA decision, featuring smaller doses or allowing for a more individualized plan for increasing dosage than offered by Novo. But analysts said that personalization strategy may not be enough to stave off new legal challenges from Novo. "It remains to be seen whether HIMS method of personalization (titration and dosage) is enough to meet the compounding clinical exemption need," said Jailendra Singh, a healthcare analyst at Truist. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-05-2025
- Business
- Yahoo
Why Novo Nordisk Stock Just Popped
President Trump threatened to levy a new 50% tariff on E.U.-imported goods last week. Novo Nordisk manufactures much of its GLP-1 drugs in Denmark. The president delayed implementation of the tariff over the weekend. 10 stocks we like better than Novo Nordisk › Over the weekend, President Trump offered to delay implementation of a new 50% tariff on imports from the European Union. The tariff, which was supposed to begin on June 1, now won't take effect until July 9. Shares of Ozempic and Wegovy manufacturer Novo Nordisk (NYSE: NVO) reacted positively to the news and are up 4.9% as of 10:20 a.m. ET. America has caught Ozempic fever, and 25% of Novo Nordisk's assets are located here in the U.S., where the company produces much of its drugs. The company also announced last year that it would spend $4.1 billion building out U.S. production facilities for Ozempic and Wegovy. Still, according to data from S&P Global Market Intelligence, 75% of Novo's assets are still located back in its home country of Denmark. That means a lot of the GLP-1 drugs that Novo sells here in the U.S. are actually produced abroad, and could be subject to the threatened 50% Trump tariff. If implementation of that tariff is delayed, that's good news for Novo. If E.U. and U.S. negotiators make use of the delay to negotiate a deal that will lower or remove tariffs entirely, that would be even better news for Novo Nordisk stock -- and it's probably what investors are actually hoping for today. Whichever way the tariff winds blow (and I've no special knowledge of that), Novo Nordisk stock remains arguably the cheapest play on the rising popularity of GLP-1 drugs. At less than 19 times earnings, Novo stock sells for a P/E ratio only one-third that of Eli Lilly (NYSE: LLY), which costs 58 times earnings. That makes Novo Nordisk stock the least risky way to play this trend. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $639,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $804,688!* Now, it's worth noting Stock Advisor's total average return is 957% — a market-crushing outperformance compared to 167% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Novo Nordisk Stock Just Popped was originally published by The Motley Fool
